Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma;Estudio comparativo entre la utilización de TSH recombinante y la estimulación endógena con TSH. Valoración en el seguimiento de los pacientes con carcinoma diferenciado de tiroides

Revista Espanola de Medicina Nuclear

Volumn 25, Issue 4, 2006, Pages 236-241

  Caresia, A P ^a   Castell Conesa, J ^a   Obiols Alfonsob, G ^a   Pifarre Montaner P ^a   Negre Buso M ^a   Garcia Alonso C ^a   Galofre Mora P ^a   Mesa Manteca, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Differentiated thyroid cancer; Radioiodine scan; Recombinant human thyrotropin; Thyroglobulin

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT HORMONE; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MALE; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY;

EID: 33747019246     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090656     Document Type: Article

References (24)

1. Gómez Camarero P, Martínez Brocca MA, Rodríguez Rodríguez JR, Navarro González E, Tirado Hospital JL, González Duarte D, et al. La TSH humana recombinante en el seguimiento de pacientes con cancer diferenciado de tiroides. Rev Esp Med Nucl. 2003;22:295-305.
2. Intenzo CM, Jabbour S, Dam HQ, Capuzzi DM. Changing concepts in the management of differentiated thyroid cancer. Sem Nucl Med. 2005;35:257-65.
3. Sánchez Franco F, Gómez JM. Cancer diferenciado de tiroides. Endocrinol Nutr. 2005;52:18-35.
4. EANM. European Association of Nuclear Medicine Procedure guidelines for therapy with iodine-131. Eur J Nucl Med Mol Imaging. 2003;30:BP27-31.
5. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, et al; Society of Nuclear Medicine Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002;43:856-61.
6. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-4.
7. Jiménez-Hoyuela García JM, García Almeida JM, Delgado Garcia A, Aguilar Fernández I, Martínez del Valle Torres MD, et al. Aplicación de la TSH humana recombinante en el protocolo diagnóstico del cancer diferenciado de tiroides Rev Esp Med Nucl. 2005;24:152-60.
8. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:619-25.
9. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9:227-47.
10. Kohlfuerst S, Igerc I, Lind P. Recombinant human thyrotropin is helpful in the follow-up and 1311 therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid. 2005;15:371-6.
11. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid. 2005;15:58-64.
12. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, et al. Serum thyroglobulin and 1311 whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 2003;148:19-24.
13. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2002;29:S492-6.
14. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002;12:37-43.
15. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-85.
16. DeGroot LJ, Kaplan EL, McCormick M, Strauss FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-24.
17. Robbins R, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001;11:865-9.
18. Serafini A, Clauss R, Levis-Dusseau S. Protocol for the combined diagnostic and therapeutic use of recombinant human thy1roid-stimulating hormone Clin Nucl Med. 2003;28:14-7.
19. Nijhuis TF, Weperem W, Klerk J. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd. 1999;21:98-100.
20. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid. 2001;11:1025-30.
21. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;25:888-96.
22. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F. Outcome of differentiated thyroid cancer with detectable serum TG and negative diagnostic (131) I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092-7.
23. Torres MS, Ramírez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab. 2001;86(4):1660-4.
24. Obiols G, Simó R, Burgos R, Tresserras R, Galofré P, Masmiquel L, et al. Carcinoma diferenciado de tiroides, 1972-1992. Estudio evolutivo, detección de recurrencias y factores pronosticos. Med Clin. 1997;109:738-43.